The real conversation about GLP-1 medications doesn't end with the prescription. Part 2 is where we get into the uncomfortable truths — the data on muscle loss, the biology of weight regain, the patient safety crisis hiding in the compounding pharmacy space — and more importantly, the complete five-pillar protocol for using these drugs with a long-game mentality. If you're on these medications, considering them, or prescribing them, this episode is required listening.

Part 1 drops alongside this one — start there if you haven't.

In this episode

• Why 39% of weight lost on semaglutide may be lean mass — and what that means for your longevity trajectory
• The muscle-longevity math: how GLP-1-driven sarcopenia can silently trade one risk for another
• Protein targets that actually matter: why the RDA is useless and what 1.6–2.4g/kg actually looks like on a plate
• The leucine threshold — why hitting 25–30g per meal is the trigger for muscle protein synthesis
• Resistance training as non-negotiable: the 2023 data showing body recomposition is achievable on these drugs
• The five-pillar MD Longevity Lab protocol: DEXA, protein architecture, resistance training, metabolic biomarkers, and the full clinical picture
• STEP 4 trial: two-thirds of lost weight regained within one year of stopping — and why that's biology, not failure
• The homeostatic counter-response: ghrelin, leptin, metabolic rate suppression, and why stopping without a foundation is dangerous
• Perimenopause intersection: two simultaneous catabolic forces and why nobody is connecting the dots for women

📝 Go deeper every week: mdlongevitylab.substack.com🌐 mdlongevitylab.com — virtual and in-person consultations available📸 @mdlongevitylab🎧 Subscribe, leave a 5-star review, and send this to someone whose provider handed them a GLP-1 prescription in a three-minute visit and called it care.